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ABSTRACT 
 
Trade Related Aspects of Intellectual Property Rights (TRIPS) is a World Trade Organization 
(WTO) agreement designed by developed countries to enforce a global minimum standard of 
Intellectual Property Rights (IPRs). There is strong concern within the international health 
community of the negative impact the TRIPS standards have on the pharmaceutical industries in 
the developing world, and in turn the production and affordability of essential medication. Under 
TRIPS, as of 2005 all countries in the WTO have to protect both product and process patents on 
pharmaceuticals, which prevents developing countries from making generic versions of essential 
medications needed to maintain market competition and meet public health demands. In 2001 the 
Doha declaration granted an extension to least developed countries until 2016 for TRIPS 
compliance, however Bangladesh is currently the only least developed country with 
pharmaceutical manufacturing capability. Therefore Bangladesh is the only country in the world 
that can still produce generic versions of new essential medications, which are needed to prevent 
a global pharmaceutical monopoly and the inevitable increase of drug prices that would result 
from the destruction of generic competition as pursued by the pharmaceutical advocates of 
TRIPS.  
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EXECUTIVE SUMMARY 
 
Over half of the world’s population lives on less than two dollars a day and cannot afford 
to purchase essential medications. Although the developing world contains eighty percent of the 
world’s population, it has less than two percent of the world’s wealth (World Bank), and 
consumes less than ten percent of the world’s pharmaceuticals, most of which are only available 
to the wealthier residents of those countries. Over 2 billion people, one third of the world’s 
population, do not have access to essential medications (WHO), and every day over 37 000 
people die from treatable infectious disease (UNICEF). 
Three decades ago, over twenty-five percent of world drug production was accounted for 
by developing and middle-income countries (Kaplan, 2006). However, over the last few decades, 
efforts to standardize international intellectual property laws have had a detrimental impact on 
the pharmaceutical industries in the developing world. This can be observed through the 
substantial decrease of pharmaceutical production in developing countries, and the centralization 
of the global drug market within the developed world. As a result, the majority of research and 
development is focused on diseases that affect the affluent population, while only one percent of 
pharmaceutical research is aimed at combating tropical illnesses which kill thousands a day in 
the developing world.  
Moreover, there is great concern within the international public health community over 
the detrimental impact current patent legislation enforced by the World Trade Organization 
(WTO) has on health in the developing world. The agreement on Trade Related Aspects of 
Intellectual Property Rights (TRIPS) was integrated into WTO legislation after enormous 
pressure from the Multinational Pharmaceutical corporations. TRIPS was developed to 
harmonize international intellectual property rights (IPRs) to a standard that is designed for the 
economic benefit of the developed countries and not appropriate for the developing and least 
developed world. Advocates of the agreement claim that strengthening IPRs across the globe will 
serve to aid international development by promoting technological transfer, foreign direct 
investment (FDI), and increased exportation from developing countries. However, further 
analysis reveals that stronger IPRs do not aid proper technology transfer, are not considered by 
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the World Bank (WB) when determining FDI, and actually lead to a greater number of imports 
to developing countries rather that exportation from.  
However, since TRIPS is part of the WTO agreements, developing countries that want 
access to the global market through the WTO must accept the TRIPS agreement, and integrate its 
IPR standards into their national legislation. Specifically, the TRIPS agreement requires that 
countries grant patents on all inventions without discrimination provided the inventions are 
considered “new” and have “industrial applications”. In addition, TRIPS requires that patents are 
granted for a period of 20 years, and allows for importation to suffice for proper “working of a 
patent” within the patenting country, which means that corporations no longer need to 
manufacture the patented product in every country in which they hold a patent. 
The prime concern for health professionals lies with pharmaceutical patents, which may 
be granted separately for the process, or the method of manufacturing each specific drug, and for 
the product itself regardless of how it is produced. The countries that today own the majority of 
the world’s pharmaceutical market, including the US, Japan, and Germany, did not grant product 
patents on pharmaceuticals until the 60’s and early 70’s when their industries had developed 
internationally competitive research and development capabilities. Although patents were always 
issued to protect the product production process, without patent restrictions on products, 
pharmaceutical companies were still able to use reverse engineering techniques on needed 
medicines to uncover their molecular structure and thus develop new ways to build the drugs that 
were needed. These compounds produced through alternate processes were then sold as 
“generic” versions of the original drug, and drove down the price of the original product through 
market competition. This generic production not only served to provide much needed 
medications, but it also greatly strengthened their pharmaceutical knowledge base and research 
capabilities.  
However, now these same countries that refused to grant product patents until well into 
the 60’s and 70’s are forcing developing countries to recognize and protect pharmaceutical 
product patents, thereby barring local production and research infrastructure development. 
Developing countries had until 2005 to implement the TRIPS legislation, and now the world’s 
primary generic distributors, India and China, are no longer able to produce much needed 
medicines at affordable prices, depriving millions of people essential medications needed to 
sustain life.  
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The TRIPS agreement contains, however, provisions designed to ensure that the 
agreement does not negatively affect public health, including compulsory licensing and parallel 
importation, but unfortunately the majority of developing countries lack the legal IP training 
needed to fully comprehend the TRIPS agreement. Moreover, in order to use the provisions, 
countries must integrate them into their national legislation, and without proper legal 
infrastructure and IPR knowledge it is virtually impossible to design TRIPS compliant 
provisional legislation.  
In 2001 as the result of pressure on the WTO from international health activists, the Doha 
declaration granted least developed countries an extension on TRIPS until 2016. For the majority 
of least developed countries, the TRIPS waiver has little benefit as they do not have 
pharmaceutical manufacturing capabilities, and even with freedom from the limits imposed by 
pharmaceutical patents, they cannot produce medicines their citizens desperately need. 
Bangladesh, however, is the only least developed country in the world with pharmaceutical 
manufacturing capabilities, and therefore is currently the only country in the world that is 
capable of producing much needed drugs at an affordable price to save millions of lives in 
developing countries across the globe.  
The annual general assembly of Health Action International Asia- Pacific (HAIAP) 
entitled “The Future of Health Services: Who Will Live and Who Will Die”, held April 10th to 
14th, 2006, on the campus of Gonoshastaya Kendra, in Savar, Bangladesh, aimed to capture the 
attention of the Bangladesh media and politicians to convince them of the critical importance of 
their country with respect to pharmaceutical production and their national patent law. The 
conference participants, health professionals from the Asia-Pacific region, Africa, and Europe, 
unanimously recommended that the government of Bangladesh should reform its patent laws to 
exclude pharmaceutical products from patent protection, as it has every right to do under the 
WTO TRIPS waiver. This would provide its pharmaceutical industries the freedom needed to 
produce generic versions of drugs that are under patent in other countries, thereby ensuring 
affordable prices on essential medications and saving millions of lives worldwide.   
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1 INTRODUCTION 
 
The developing world, which contains 80% of the world’s population, owns less than 2% 
of the world’s wealth, and consumes less than 10% of the world’s pharmaceuticals. Over half of 
the world’s population lives on less that two dollars a day, and one third of the world’s 
population does not have access to essential medications (WHO). Every day over 37 000 people 
die in the developing world from treatable preventable disease (UNICEF).  
Although three decades ago over 25% of the world’s pharmaceuticals were produced in 
developing and middle income countries (Kaplan, 2006), the current pharmaceutical market is 
centered in the developed world where over 90% of all pharmaceuticals are consumed. This is 
reflected in the research and development areas pursued by the major pharmaceutical industries, 
which are focused on diseases that affect the developed world and ignore the needs of 
developing countries because there is little market incentive to develop drugs for the poor. In 
addition, pharmaceutical companies claim that they must charge high prices for their products to 
recoup research and development expenses and fund further research projects. However, analysis 
reveals that all of the of the nine major US pharmaceutical companies that market top 50 drugs 
spend on average at least twice as much money on marketing than they do on research and 
development.  
 Moreover, developing countries are being forced to follow World Trade Organization 
(WTO) enforced patent legislation that is not supportive of their emerging pharmaceutical 
industries, which has lead to the foundering of their research and development capabilities. In 
contrast, when industrialized countries that currently lead the world pharmaceutical markets were 
still developing their pharmaceutical industries, they followed the Paris Convention on 
intellectual property that allowed countries the freedom do decide on the areas of patentability 
and the duration of patents. With respect to pharmaceutical patents, countries were able to 
protect process patents and exclude product patents. This provided nations with the freedom to 
investigate invented medicines through reverse engineering techniques to determine their 
structure and create new synthetic routes for production. They could then produce “generic” 
versions of the same drug from this new production process, providing their citizens access to 
quality drugs at affordable costs, while simultaneously strengthening their national 
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pharmaceutical industries. These developed countries did not adopt product patents on 
pharmaceuticals until the late 60’s and 70’s after their pharmaceutical industries had reached an 
internationally competitive level. 
However, now these same countries that refused to grant product patents until well into 
the 60’s and 70’s are forcing developing countries to protect pharmaceutical product patents, 
thereby barring local production and research infrastructure development. In 1995 the Trade 
Related Aspects of Intellectual Property Rights (TRIPS) agreement was born with the WTO 
through pressure from multinational corporations who wanted to harmonize international 
Intellectual Property Rights (IPRs). As members of the WTO, the TRIPS agreement must be 
adopted by all countries that want access to the global market, regardless of their stage of 
development. Although TRIPS advocates argue that the agreement will aid international 
development, analysis into technology transfer, foreign direct investment (FDI), and exportation 
from developing countries reveals the fallacy of this claim.  
Moreover, health professionals from across the globe are outraged by the impact TRIPS 
has had on developing pharmaceutical industries. Developing countries had until 2005 to become 
TRIPS compliant, and now the world’s major generic drug producers India and China can no 
longer produce generics of new medications because they are now obligated to protect product 
patents under TRIPS. The generic market is extremely important for both the production of 
needed medications and the maintenance of generic competition that prevents corporations form 
charging exorbitant prices on medications. It is imperative that generics are produced to prevent 
a pharmaceutical monopoly from bringing the prices of essential medications further out of reach 
of the world’s suffering poor. 
In 2001 as the result of pressure on the WTO from health activists, the Doha Declaration 
granted a waiver on TRIPS compliance until 2016 for least developed countries. However, 
Bangladesh is the only least developed country with pharmaceutical manufacturing capability, 
and is therefore the only country in the world that is capable of producing generic versions of 
new medications without repercussions from the WTO. If Bangladesh revises its national patent 
legislation to exclude product patents on pharmaceuticals, then it will save millions of lives 
through the production of affordable essential medicines, and will in turn provide generic 
competition to the larger corporations to ensure reasonable prices on pharmaceuticals. 
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2 DEVELOPING WORLD 
 
The developing and least developed world contains 80% of the world’s population, and 
less than 2% of the world’s wealth (World Bank). Developing countries consume less than ten 
percent of the world’s pharmaceuticals, most of which are consumed by the wealthier residents 
of those countries. WHO estimates that 2 billion people, or one third of the world’s population, 
do not have access to essential medicines, and UNICEF states that every day over 37 000 people 
die in the developing world from treatable infectious diseases. This section explores the current 
state of developing countries with specific attention to their lack access to medicines.  
2.1 Classification of Developing & Least Developed Countries 
The human development index (HDI) is a widely accepted measure of a country’s stage 
of development, and compares among other things measures of poverty, literacy, education, life 
expectancy, child welfare, and standard of living as measured by gross domestic product (GDP) 
per capita at purchasing power parity (PPP). Although the United Nations (UN) does not have an 
official designation for “developed” or “developing countries”, the measure of the HDI is widely 
considered a determinant for this distinction. Developed countries enjoy a high standard of living 
through a high GDP as the result of their industrialized economy, and countries commonly 
accepted as developed include Japan (GDP$ 36,596), Canada ($31,134), the United States 
($39,935), Australia ($30,682), New Zealand ($23,846), and majority of the European countries.  
Developing countries on the other hand have a relatively small industrial base, and a low 
standard of living compared to the industrialized countries as reflected in their HDI represented 
in Figure 1. Although the GDP per capita of developing countries varies from over $10,000 to 
just $90, there are 59 countries that survive on under $1000 per capita GDP. In the 1960’s the 
UN recognized that special attention was needed for a number of countries who should not be 
grouped in with developing nations because they have experienced prolong periods of economic 
decline. The first resolution on the least developed countries (LDC) was adopted at UNCTAD II 
in 1968, and the UN created the first list of LDCs in 1971. Least developed countries are 
determined through the following:  
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• A “low-income” criterion based on a three-year average estimate of the gross national 
income (GNI) per capita (under $750 for inclusion, above $900 for graduation to the 
category of “developing nation”). 
• A “human resource weakness” criterion based on indicators of nutrition, health, 
education and adult literacy. 
• An “economic vulnerability” criterion based on instability of agricultural production, 
exports of good and services, merchandise export concentration, handicap of economic 
smallness, and percentage of population displaced by natural disasters.  
Of the LDCs, there is also special classification for countries that are landlocked and countries 
on small islands, supporting the theory that geographical isolation has a strong impact on a 
country’s economic development. Currently, there are 50 countries on the LDC list, sixteen of 
which are landlocked and twelve of which are small islands. 
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Figure 1: World Map Indicating HDI of UN Member States, 2003 
 
 
2.2 Distribution of Global Wealth 
The wealth of the world’s nations can be measured in many ways and varies substantially 
by level of income across different regions. Current assessments of these variations recognize 
that the wealth of a nation does not rest solely on the income of its residents, and recent studies 
have encompassed values for agricultural land, minerals, forests, produced assets, and intangible 
capital including but not limited to raw labor, human capital, social capital, and quality of 
institutions. An assessment encompassing so many different sources of wealth was used by the 
World Bank in a recent publication entitled The Wealth of Nations, which produced the values of 
global wealth distribution illustrated in Figure 2. While it is very important to assess the full 
capacity of a country’s natural resources and intangible assets for sustainable development policy 
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approaches, it is important to keep in mind that the resources included in such assessments are 
often not distributed among the entire populations of developing countries. 
 
Figure 2: Global Distribution of Wealth (2000)
1
 
 
                                                
1 World Bank, Where Is the Wealth of Nations? (2006). 
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Figure 3: The Poverty Lines: Population Living with Less than 2 Dollars  
and Less than 1 Dollar a Day
2
 
                                                
2 http://www.povertymap.net 
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Therefore, even though the country might have a significant amount of wealth as calculated by 
the World Bank (WB), these calculations are not an adequate representation of the wealth of the 
common citizen who does not have access to such resources and will not feel the benefits of their 
worth. Moreover, as this measure of wealth is not parallel to the income of the majority of 
citizens in developing countries, it cannot be used as an estimate of their purchasing power. 
This lack of wealth is especially important when considering access to essential medicines, and 
the ability of the common citizen to afford them. Figure 3 presents a more accurate 
representation of the ability to purchase medicines in the developing world, as it illustrates the 
vast numbers of people who live on less than one or two dollars a day, and cannot even afford 
sufficient daily sustenance. As of the year 2000, 1.3 billion people live on less than one dollar a 
day; and half of the world, nearly 3 billion people, lives on less than two dollars a day. More than 
1.3 billion do not have access to clean water; 3 billion do not have access to sanitation; and 2 
billion do not have access to electricity (Wolfenson, 1998).  In contrast, a few hundred of the 
world’s millionaires have as much wealth as the world’s poorest 2.5 billion people, over one 
third of the global population. The combined incomes of the population in the 50 least developed 
countries, where the world’s poorest 582 million live, is $146 billion, or 0.15% of the income of 
the world’s richest 200, which reached $1 trillion in 1999 (UN, 2000). Moreover, the GDP of the 
poorest 50 nations, one quarter of the world’s countries, is less than the wealth of the three 
richest people in the world (Ramonet, 1998).  
2.3 Population 
The current and projected population of developed countries and developing countries as 
compared to the total world population is illustrated in Figure 4.  The least developed and 
developing countries currently constitute 81% of the world’s total population, while the most 
developed countries constitute less than 19% of the world’s population. In addition, while the 
birth rate of the most developed countries is predicted to remain fairly constant over the next 
forty years, the birth rate in the developing world is increasing, accounting for the large predicted 
increase in global population. 
 20 
 
Figure 4: Projected World Population Growth  
(Least developed already included in less developed value)
3
 
 
This population increase is expected to be concentrated mainly in the Asia Pacific region 
and Sub-Saharan Africa as illustrated in Figure 5. It is theorized that since developed countries 
have a high standard of living, they are more conscious of the number of children they have due 
to the high cost of raising and educating children in the developed world. Furthermore, citizens 
of developed countries have ready access to contraceptives and are usually able to control their 
pregnancies. In contrast, contraceptives in the developing world are often unheard of, and it is 
not uncommon for women to have upward of seven or eight children. The lack of contraceptives 
and awareness about birth control methods is also a main catalyst for the spread of aids, as very 
often women in the developing world are uneducated about the threat of the disease. 
 
                                                
3 http://esa.un.org 
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Figure 5: Rural and Urban Predicted World Population Increase  (1960-2025)
4
 
 
The estimated world population for 2015 is illustrated on a global map in Figure 6. 
Overall, the predicted increase in the population of the developing world has serious implications 
for the state of international public health. Currently the developing world constitutes over 80% 
of the world population, but owns less than 2% of the world’s wealth, and consumes less than 10 
% of the world’s medications. Unless access to and affordability of these medications is 
improved, then the 1/3 fraction of the world’s population that does not have access to essential 
medicines will only increase, and the current number of 37 000 people that die a day from 
treatable infectious disease will continue to climb. 
 
                                                
4 Rekacewicz, P. World Bank. (2001). 
 22 
 
Figure 6: Global Population Densities 2005
5
 
 
2.4 Public Health 
Although this paper focuses specifically on access to essential medicines in the 
developing world, it is necessary to mention the complex nature of international public health, 
and the numerous barriers to public health that must also be addressed. These include but are far 
from limited to proper nutrition, access to clean potable water, and access to sanitation. While 
medical treatment is necessary, working to provide these basic health necessities will greatly 
reduce the level of disease and sickness in the developing world, and greatly reduce the number 
                                                
5 Poverty Mapping Urban Rural (PMUR) Database, www.povertymap.net. 
 23 
of deaths from preventable diseases. The UN Millennium Development Goals were created to 
inspire global cooperation to fight these barriers and to improve the basic health and standard of 
living in the world’s developing and least developed countries.    
Within the developing world where countries are indebted and struggle to provide health 
services to their populations, even in best case scenarios, upwards of 25-70% of overall health 
care expenditure is spent on the purchase of medications, compared with 15% in developed 
countries (WHO, 2004). Even with this high expenditure, medicines still do not reach large 
numbers of the populations. Moreover, in countries with inadequate health care financing 
systems, it is up to the individual households to purchase their own medications. As illustrated 
previously, for the 3 billion people who live on less than two dollars a day and cannot afford 
basic sustenance, the current cost of medicines is extremely impossible to meet. In such cases 
when there is no government or international support, it is the poor and sick that suffers the most, 
and have no voice in global affairs to defend their right to medicines readily available in the 
developed world. WHO estimates that in some countries half the people living in poor 
households, some 1.7 billion people receive none of the essential medicines needed to treat acute 
illnesses. The result, as deserves repeating, is over 37 000 people die a day from treatable 
infectious disease (UNICEF). 
A main measure of the development of a country lies in the welfare of its children. The 
total number of children in the world is 2.2 billion, and one billion of these, or every second 
child is born into poverty. Across the globe, 1.4 million children die each year from lack of 
access to safe drinking water and proper sanitation. Of the 1.9 billion children in the developing 
world (86% of the world’s children), one third do not have adequate shelter (640 million, 29% of 
world’s children), one fifth do not have access to safe drinking water (400 million, 18% of 
world’s children), and one seventh do not have access to health services (270 million, 12% of 
world’s children). In 2002 at least 3.5% of the world’s children died from preventable disease 
because they were born into this overwhelming poverty and were not provided with life-saving 
medicines. In that year one million children died from malaria, another 2 million child deaths 
were caused by perinatal diseases, and 4 million more from pneumonia, measles, and diarrhoea 
(WHO). That results in a bare minimum count of 7 million child deaths in developing countries 
in 2002 from mostly preventable diseases that are no longer a threat to the developed world 
where medicine for treatment and prevention is readily available. In 2003, it is estimated that in 
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the developing world, 10.6 million children died before the age of 5, which equals the total child 
population of France, Germany, Greece, and Italy (UNICEF, 2005).  
 In the year 2002 alone, there were over 6 million deaths from malaria, TB, and AIDS.  In 
addition, millions of people, especially children, lose their lives to completely preventable 
diseases like pneumonia, measles, and diarrhoea. Other major causes of death common to high 
and middle income countries that are now becoming an increasing problem in low income 
countries include heart disease, stroke, and cancer. A major turning point in the field of 
international public health was brought about by the huge impact of AIDS on the global 
population. The aids virus spread from 6.3 million people in 1988 to over 40 million people in 
2003, and it is estimated that 2.5 million of the infected are children. Furthermore, Sub-Saharan 
Africa is home to 30% of the aids cases, even though it only holds 2% of the world’s population. 
The epidemic threat of the AIDS virus has shed light within the international community upon 
many problems in medicine policy. Namely, since AIDS is a disease that affects developed 
countries, there is a huge demand for and substantial amount of research being done to find cures 
for the virus.  The anti-retro viral therapies (ARVs) that have been developed by the major 
pharmaceutical corporations are desperately needed by people in the developing world, and 
NGOs have been insistently pleading their concerns over the high prices and inaccessibility of 
the ARV treatments. While the problems of accessibility and affordability have always existed 
with pharmaceuticals, AIDS holds a stronger pull on the international community because it is 
not an isolated disease seen only in the poorest countries, but it is also on the front door of many 
of the wealthiest neighborhoods in the developed world. Unfortunately, at the same time that 
AIDS was getting the attention of the global community, the pharmaceutical community was 
simultaneously pressuring developing countries, through the World Trade Organization, to sign 
legislation protecting pharmaceutical patent rights to remove their freedom to make generics of 
the newly developed ARVs and other essential medicines.  
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3 PHARMACEUTICAL INDUSTRIES AND DEVELOPMENT 
 
 Pharmaceutical markets are concentrated in the developed world, which consumes 90% 
of the world’s pharmaceuticals. The research and development of these markets are centered on 
illnesses that are common in affluent countries, ignoring the needs of the majority of the world’s 
population who suffer from neglected tropical disease. In addition, while there are treatments 
available for diseases that kill over 37 000 a day in the developing world, the high prices of these 
therapies are unaffordable for more than one half of the global population living on less than 2 
USD a day. Pharmaceutical companies claim that the prices are needed to recoup costs for past 
and future research and development, however an analysis of the revenue allocation of the ten 
top pharmaceutical corporations reveals the fallacy of this claim as the majority of revenue is 
spent on marketing and advertising or harbored as net profit. 
3.1 Major Pharmaceutical Markets 
The global pharmaceutical market is concentrated in a select number of developed 
nations as illustrated in Figure 7.  The pharmaceutical industry is centered in North America with 
40% of the market, and Europe and Japan constituting together about 40% of the market. Latin 
America contributes about 6%, China less than 2%, and South Korea, Australia, and India     
     
Figure 7: World-Wide Pharmaceutical Market (1999) USD in billions
6
 
                                                
6 IMS World Review (2000). 
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each approximately 1%. It can easily be observed from the chart that developing countries, 
which aside from India are classified as “other”, constitute less than 5% of the pharmaceutical 
market, even though they constitute more than half of the global population. A more recent 
analysis covering the years 2001 and 2005 is provided in Figure 8, which illustrates the world’s 
largest pharmaceutical markets, constituting 79.1% of the industry. There is an obvious shift in 
the control of the market, with the United States alone controlling over 51% of the world’s major 
pharmaceutical sales.  An estimate of the WHO states that over 90% of the world’s 
pharmaceuticals are consumed by just 15% of the population.  
      
Figure 8: World’s Largest Pharmaceutical Markets (79.1% of Total Market) 
  In stark contrast, over two decades ago 25% of world drug production was accounted for 
by developing and middle-income countries as illustrated in Table 1 (Kaplan, 2006). In 1992, 
multinational drug companies in 10 industrialized countries had a substantial research and 
development base capable of supporting innovation of new chemical entities, while Argentina, 
China, India, Korea, and Mexico had innovative capabilities to manufacture new drugs and 
develop generic copies of existing drugs. 
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Number of Countries Stage of Development 
Industrial Developing Total 
Sophisticated pharmaceutical 
industry with a significant research 
base 
10a 0 10 
Countries with innovative 
capabilities 
12 5b 17 
i) Those producing both 
therapeutic ingredients and 
finished products 
6 8 14c 
ii) Those producing finished 
products only 
2 87 89 
No pharmaceutical industry 1 59d 60 
Totals 31 159 190 
Table 1: International Pharmaceutical Manufacturing Capabilities in 1992
7
 
a. (United States, Japan, 8 countries in Western Europe) 
b. Argentina, Chine, India and Mexico 
c. European and higher income Latin American (e.g. Brazil) and Asian countries 
d. Primarily African countries and small islands 
 
In addition, there were national drug companies in eight developing countries within Latin 
America and Asia that were capable of producing both therapeutic ingredients and finished 
products, and there were national drug companies in 90 developing countries capable of 
producing finished products only (Balance, 1992). Finally, there were 59 developing countries 
that had no pharmaceutical manufacturing capabilities. In 1995 with the creation of the World 
Trade Organization (WTO) and the introduction of the Agreement of Trade Related Aspects of 
Intellectual Property Rights (TRIPS), pharmaceutical manufacturing capabilities in the 
developing country were greatly damaged by the introduction of product patents. The broad 
impact that the TRIPS agreement has had on developing countries and their pharmaceutical 
markets is explored further on in the paper. 
                                                
7 Balance, The World’s Pharmaceutical Industries: An International Perspective on Innovation, 
Competition, and Policy, (1992) quoted in Kaplan, W. Laing, R., Is Local Production of 
Pharmaceuticals A Way to Improve Pharmaceutical Access in Developing and Transitional 
Countries? (2006). 
 28 
3.2 Research and Development 
 As the world’s pharmaceutical market is centered in the developed world, the research 
and development pursued by the major companies is focused on disease and illness that affects 
the affluent and not on the diseases that affect the largest portion of the world’s population. 
Pharmaceutical companies work for profit, and they develop medications that are demanded in 
the developed world for which they will be able to recoup R&D costs and additional profits. 
Table 2 illustrates the current focus of the pharmaceutical industries, and as can be observed the 
ten leading medicines account for 31% of global sales. In the listed therapies, there are six major 
therapeutic areas that account for 85% of medicinal sales - cardiovascular, central nervous 
system, metabolic, infectious, respiratory, and musculo-skeletal disease - which together account 
for the burden of disease in the developed world. 
Rank Audited World 
Therapy Class 
2000 Sales 
(US$Bn) 
% Global Sales % Growth 
Year-Over-
Year 
1 Antiulcerants 17.4 5.5% 13% 
2 Cholest & Triglyceride 
Reducers 
15.9 5.0 21 
3 Antidepressants 13.4 4.2 18 
4 Calcium Antagonists 9.8 3.1 2 
5 Antirheumatic Non-
Steroidials 
9.5 3.0 26 
6 ACE Inhibitors, Plain 7.3 2.3 3 
7 Cephalosporins & 
Combinations 
6.9 2.2 -5 
8 Antipsychotics 6.0 1.9 22 
9 Non-Narcotic 
Analgesics 
6.0 1.9 3 
10 Oral Antidiabetics 5.9 1.9 26 
 Total Leading 10 
ATC’s 
$98.2 31.0% +13% 
Table 2: Analyses of U.S. Research and Development Areas (2000)
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 Meanwhile, in the developing world infectious and parasitic diseases rage, and there is 
extremely limited research aimed at combating such diseases. Within the past 25 years only 1% 
of pharmaceutical research and development was aimed at Tropical Diseases and Tuberculosis, 
which account for over 11% of global disease (WHO, 2004). Neglected diseases including 
                                                
8 Families USA, Off The Charts: Pay, Profits and Spending by Drug Companies (2001). 
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trypanosomaisis (sleeping sickness), Buruli ulcer, and Chagas disease cause great suffering and 
death in the developing world and have no suitable treatments. Although there are hundreds of 
millions at risk for these diseases, and some threaten to return to levels not seen for 75 years, the 
populations who are suffering have no purchasing power, and therefore there is little incentive 
from pharmaceutical markets for companies to pursue research and development for these 
neglected diseases.  
3.3 Revenue Allocation 
 Pharmaceutical companies claim to charge high prices on their manufactured drugs to 
recoup research and development costs and support future research endeavors. An analysis by 
Families USA of the profits and spending of Drug Companies reveals the fallacy of this claim as 
illustrated in Table 3. All of the nine major US pharmaceutical companies that market top 50   
Percent of Revenue Allocated Company Revenue  
(Net Sales in 
Millions $US) 
Marketing/ 
Advertising/ 
Administration 
R&D Profit  
(Net Income) 
Merck and Co., Inc 40,363 15% 6% 17% 
Pfizer Inc. 29,574 39% 15% 13% 
Bristol-Myers Squibb 
Company 
18,144 30% 11% 26% 
Pharmacia Corporation 13,746 37% 15% 4% 
Abbott Laboratories 13,263 21% 10% 20% 
American Home Products 
Corporation 
10,862 38% 13% -18% 
Eli Lilly and Co. 9,815 30% 19% 28% 
Schering-Plough 
Corporation 
1,563 36% 14% 25% 
Allergan, Inc. 1,563 42% 13% 14% 
Table 3 Analysis of U.S. Pharmaceutical Revenue Allocation (2000)
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drugs spend on average at least twice as much money on marketing and advertising then they do 
on research and development. In addition, six of the nine made more in net profits then they 
spent on R&D, and three, Merck, Bristol-Myers Squibb, and Abbott Laboratories received twice 
as much in net profit as they spent on R&D. In addition, as can be viewed in Table 4, the average 
and median compensation for the highest paid executive in each of the nine major  
                                                
9 Families USA, Off The Charts: Pay, Profits and Spending by Drug Companies (2001). 
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Company Executive Total Compensation 
Abbott Laboratories Robert L. Parkinson, Jr. Retired 
President and C.O. 
$ 6,484,284 
Allergan, Inc. Lester Kaplan, Corporate VP and 
Pres. R&D 
$ 13,271,881 
American home 
Products Corporation 
John R. Stafford, Chairman and 
CEO 
$ 27,008,927 
Bristol-Myers Squibb 
Company 
M.F. Mee, Executive VP & CEO $ 6,924,102 
Ell Lilly and Co. Sidney Taurel, Chairman, President 
and CEO 
$ 18,788,703 
Merck and Co. Inc. Edward M. Scolnick, Executive VP $ 26,454,600 
Pfizer Inc, William C. Steere, Jr., Chairman $ 40,191,845 
Pharmacia Corporation Phillip Needleman, Senior Exec, 
V.P. 
$ 9, 305,888 
Schering-Plough 
Corporation 
Richard Jay Kogan, Chairman and 
CEO 
$ 21,444,020 
Table 4 Highest Compensation Package by Company,  
Exclusive of Unexercised Stock Options
10
 
 
pharmaceutical companies, exclusive of unexercised stock, was almost $19 million USD in the 
year 2000. These figures plainly refute the argument that high prices must be charged on all 
medications to support research and development costs, as the majority of revenue is not put 
towards research and development, but marketing, advertising, compensation packages, and 
stock. 
  
                                                
10 Families USA, Off The Charts: Pay, Profits and Spending by Drug Companies (2001). 
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4 INTELLECTUAL PROPERTY RIGHTS (IPRs) 
 
Since the industrial revolution, Intellectual Property Rights (IPRs) have played a 
dominant role in the development of industrialized economies. By protecting the rights to 
inventions, IPRs stimulate more innovation from individuals and corporations, in turn improving 
the development of industrialized society. However, outside of the industrialized nations, IPRs 
do not serve the same role. During the development of modern industrialized countries, 
international IPR legislation through the Paris Convention was flexible, allowing countries to 
exclude certain technologies from protection and determine on their own the length of protection 
afforded. This gave countries the freedom to adapt their own national legislation to suit their 
specific development needs at various time periods, especially with respect to pharmaceutical 
patents. In parallel, developing countries of today who lack indigenous technological capability 
need the freedom to adapt their own legislation to encourage transfer of technology, increase 
foreign investment, and in turn support the development of their own industries. However, major 
global corporations fear loss of revenue from weak IPR regulations around the world, and during 
the Uruguay Rounds put pressure on the rest of the international community to adopt IPRs into 
world trade agreements. This pressure resulted in the implementation of the agreement of Trade 
Related Aspects of Intellectual Property Rights (TRIPS), which must be adopted by any country 
wishing to join the World Trade Organization and have access to the global market.  Under 
TRIPS, developing countries are required to meet developed country standards on IPRs, severely 
damaging their own industrial growth, most notably that of their pharmaceutical industries. 
4.1 Role of IPRs: Patents 
IPRs cover many areas of creative works, including inventions, literary and artistic 
works, symbols, names, images, and designs as used in commerce. A major branch of IPRs 
involve patent rights, which are awarded by society to individuals or organizations for creative 
works and knowledge, and provide the right to prevent others from making, selling, distributing, 
importing, or using their invention without authorization for a limited period of time. The 
inventor must then in return disclose the invention to society so that others can put it into 
practice, increasing the wealth of knowledge for further research. In order to qualify for patent 
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protection, an invention must be novel, non-obvious, and have utility (as in US) or industrial 
applicability (as in Britain).  
Protecting the rights of inventions under patents provides incentives for individuals and 
organizations to invest in innovation and development. When an invention is copied and 
produced at a fraction of the cost taken to develop it, then the inventor loses on his return, and 
will no longer invest time in new inventions, which is referred to as market failure and would in 
turn impeded the development of society as a whole.  
4.2 Intellectual Property and Development 
 The development of economies in developing countries is primarily a reflection of their 
indigenous technological capability and their research and innovation capability. In order to 
build technological capacity, developing countries require substantial transfer of basic 
technologies, which they may dissect and absorb into their own technological capacity. In 
addition, they require increased foreign direct investment and greater exports to stimulate 
research and development within their industries. It is theorized by developed countries that 
increased IPR will serve to increase technology transfer, FDI, and exports, thereby strengthening 
indigenous technological capability in developing countries and improving their respective 
economies. However, with patent protection also comes major restrictions on the ability of 
developing countries to use the same reverse engineering techniques used by today’s developed 
countries during their industrial developments limiting developing countries’ ability to build 
their industries in the same manner as today’s developed countries. Moreover, patent protection 
is designed fundamentally to protect and stimulate innovation, and the majority of today’s 
developing countries do not currently possess innovative capabilities worth protecting. 
Therefore, the application of international IPRs in developing countries must be evaluated with 
respect to the development of their technological capacity, especially with respect to 
pharmaceutical research, development, and manufacturing capabilities. This theme will be 
explored further throughout the paper. 
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4.3 The Evolution of International Intellectual Property Legislation 
 While the world’s current industrialized nations were developing, the Paris Convention 
was the governing international legislation on IPRs. The Paris Convention allowed room for 
individual countries to adapt their own legislation to meet their individual development needs by 
allowing nations to exclude certain technologies from patent protection, and to determine the 
length of protection afforded to them. Namely, with respect to pharmaceutical patents, countries 
were able to only protect process patents and not product patents, allowing their developing 
industries to take products from other counties and use reverse engineering techniques to find 
new synthetic routes to product development. This not only allowed the developing industries to 
manufacture needed medicines, it also helped them build their research infrastructure and 
synthetic knowledge base. Those same countries, which now have the strongest pharmaceutical 
industries, refused to grant product patents in their countries until their industries reached an 
internationally competitive level. However, with the introduction of TRIPS, developed countries 
are forcing the developing countries to protect product patents, which developed countries 
themselves refused to do until the late sixties and seventies. This is not only causing great 
damage to the pharmaceutical industries in developing countries, but it is also destroying the 
generics markets, thereby raising the price of needed pharmaceuticals and putting essential 
medicines even further out of reach in the developing world and killing tens of thousands daily. 
4.3.1 International Trade Organization (ITO) 
Although the United States has always participated in international trade, it did not adopt 
an active role within global trade policy until after the Great Depression. While Congress had 
always been responsible for promoting and regulating commerce as outlined in the constitution, 
foreign policy negotiations had been the exclusive responsibility of the executive branche. This 
division of powers has resulted in a constant governmental battle over the compromises needed 
to promote trade and protect industry (Aaronson, 2001). To remedy this situation, in 1934 the 
Reciprocal Trade Agreement Act was passed. This law provided the US government the 
authority to enter into bilateral agreements for reciprocal tariff reductions.  
After the great depression and the economic hardship of the Second World War, many 
industrialized nations recognized the value of negotiating an order to govern monetary relations 
between independent nation states. The United States at the time was the world economic 
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powerhouse, and took the lead role in organizing the conference and spear-heading the agenda. 
From July 1st to 22nd, 1944, over 730 delegates from 45 Allied nations gathered in Bretton 
Woods, New Hampshire at the Mount Washington Hotel for the United Nations Monetary and 
Financial Conference. This conference resulted in the signing of agreements to construct the 
International Monetary Fund (IMF), and the International Bank for Reconstruction and 
Development (IBRD), which is now part of the World Bank (WB). In addition, the Bretton 
Woods Conference proposed the creation of an International Trade Organization (ITO) that 
would establish rules and regulations for trade between countries, and act as “the third pillar of 
the post war liberal international economic order.” (Sneyd, 2005)  
The ITO was originally designed with the main goal of supporting development, and was 
greatly influenced by the theories of John Maynard Keynes. It “represented an internalization of 
the view that governments could play a positive role in encouraging international economic 
growth” (Aaronson, 2001), and was drafted with loopholes and freedoms for developing 
countries to maintain legislation that would be supportive of their individual countries needs. 
Specifically, the Charter’s “most distinctive feature was the integration of an ambitious and 
successful program to reduce traditional trade barriers, with a wide-angled agreement that 
addressed investment, employment standards, development…. [I]t pioneered the idea that trade 
disputes had to be settled by consultation and mediation rather than legal clout” (Drache, 2000). 
The preparatory committee formed at Bretton Woods worked four years drafting the ITO 
Charter, which was signed in March 1948 by fifty-three nations. 
4.3.2 General Agreement on Trade and Tariffs (GATT)  
Through the years of the ITO Charter development, export-oriented nations were 
simultaneously negotiating tariff concessions in a separate process. These negotiations resulted 
in the General Agreement on Tariffs and Trade (GATT), which is based on the “unconditional 
most favored nation principle”: that is, the conditions that apply to the least restrictive trading 
nation also apply to all other trading nations. The GATT agreement was signed by twenty-three 
nations in January 1948, just months before the ITO Charter. Many developing nations assumed 
that GATT was going to be incorporated into the more comprehensive ITO Charter, and they 
feared that if they did not sign the GATT agreement then the more powerful nations would not 
support the ITO. However, although the ITO Charter was signed in 1950, President Truman 
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stated that he was not going to bring the Charter in front of Congress, claiming that the Charter 
was not supported by the Senate or export-oriented corporations. Many critics believe that the 
block was prompted by fears within the American business community that the International 
Trade Organization could be used to regulate, rather than liberate, big business (Wilkins, 1997). 
The US was the global leader for international trade agreements at the time, and without US 
ratification the Charter, was essentially nullified for the international community. Therefore, by 
not seeking ratification of the Charter President Truman simultaneously blocked the birth of the 
ITO (Sneyd, 2005), leaving in its place the GATT agreement as the governor of world trade. The 
fight of developing nations to adapt international trade policy to accommodate their need for 
development has been raging ever since. 
4.3.3 Paris Convention 
The first international agreement on Intellectual Property Rights was signed in Paris, 
France on March 20th, 1883 and is known as the Paris Convention for the Protection of Industrial 
Property. This agreement held the guiding principle that public interests must take precedence 
over commercial interests, and therefore allowed for flexibility within national Intellectual 
Property Rights legislation to allow each country to cater their policy to meet their individual 
development needs. The developed countries of today were still developing at the time and took 
full advantage of the Paris Convention provisions to allow their developing industries access to 
needed technologies, most notably pharmaceuticals. 
Primarily, the Paris convention provided the freedom for countries to decide on the areas 
of patentability and duration of patents. Many countries decided not to provide patent protection 
for pharmaceutical products or medicines, but rather only grant patents for the processes, or the 
method of manufacturing each specific drug. These process patents were granted for a period of 
seven to ten years, but did not impede the transfer of pharmaceutical knowledge and 
technologies because of reverse engineering strategies used in the developing world. Granting 
process and not product patents allowed other nations to investigate newly invented medicines to 
determine their chemical structure, then work backwards and deduce step-by-step possible 
synthetic routes for production. Other nations could then produce a generic version of the same 
drug through a different synthetic route, providing their citizens access to quality drugs at an 
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affordable costs, while simultaneously strengthening national pharmaceutical industries by the 
mere investigation of foreign medicines. 
In addition, article 5b of the Paris Convention obliged the patent owner to work the patent 
in the country that grants process patent protection, that is, the product had to be manufactured in 
every country to which patent protection was granted. Importing of the product does not qualify 
as “working the product”; therefore patenting a product in a particular nation was a serious 
commitment to ensure the manufacturing of that product. 
Finally, the Paris convention also allowed governments to issue compulsory licensing if 
the protected patent was not being worked in the named country and the drug was not regularly 
available. Under these circumstances the government that required the drug could authorize a 
domestic drug company to manufacture the drug after paying a compensation fee to the patent 
holder.  However, “a compulsory license may not be applied for on the ground of failure to work 
or insufficient working before the expiration of a period of four years from the date of filing of 
the patent application or three years from the date of the grant of the patent, whichever period 
expires last.” (Paris Convention, 5A4)  
Many researchers note that a patent free environment was essential for the growth of 
pharmaceutical industries, which is reflected in the fact that the countries with today’s most 
successful pharmaceutical industries refused to grant patent protection on medicines until they 
had reached a certain standard of development. Most notably, France was the first country to 
introduce product patents in 1960, followed by Germany in 1968, Japan 1976, Switzerland 1977, 
Italy and Sweden in 1978. (K. Balasubramaniam, 1996)  The United States specifically stated 
that it was freely entitled to foreign works to further its social & economic development, despite 
British retaliation (US Congress, 1986).   
4.3.4 World Trade Organization (WTO) 
The GATT national memberships increased substantially from 1948 until 1993. Within 
that time eight different rounds of trade negotiations were held between member nations. During 
these negotiations while the developed countries had “hundreds of trained specialists in all fields 
available to discuss all issues, underdeveloped countries usually were only able to send one trade 
counselor who was shuffled from meeting to meeting with no real understanding of issues 
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against all specialists” (Balasubramaniam, 1996). The working groups were arranged by the 
presiding officer with no attempt to balance the groups with representation from developed and 
developing countries. Furthermore, in the negotiation rounds developing country representatives 
were not included in the important sessions and were left in the dark on the major decisions, only 
to be consoled into negotiation when their votes were required. Moreover, the rounds were 
withheld from the public and respective ministries of all involved countries, and there were no 
recordings made of the negotiations so it is impossible to fully analyze their evolution. With the 
developing countries extremely over faced and ill prepared to fight against the developed 
countries, the rounds resulted in industrialized-favored agreements that left the needs of the 
developing countries in the dust. Specifically, these negotiations resulted in reduced tariffs, 
special-case treatments of individual products, and certain special exceptions and modifications 
for each country. 
The final round of negotiations, known as the Uruguay Round, lasted eight years, from 
September 1986 until April 1994, and resulted in the “Final Act” and the creation of the World 
Trade Organization (WTO). This new institutional organization was aimed at increasing 
international trade by lowering trade barriers, and allowing maximum freedom for corporate 
decision making, minimizing the role of national governments in the economy 
(Balasubramaniam, 1996). The Final Act involved the integration of international trade issues 
with legislation designed to increase the accessibility of Trans National Corporations (TNCs) to 
national economies. While GATT had always ensured that member nations had the freedom to 
determine their own rules governing domestic agriculture, intellectual property rights, foreign 
investment, infrastructural services, professional services, and health and safety standards, the 
new international agreement incorporated rules governing these national interests into the 
previous GATT Legislation. 
4.4 Trade Related Aspects of Intellectual Property Rights (TRIPS) 
The main result of the final negotiations was the creation of the agreement on Trade 
Related Aspects on Intellectual Property Rights (TRIPs), which was integrated into WTO 
regulation. The agreement created a global standard for IPRs, and any nation wishing to be part 
of the WTO must adapt their laws to meet these standards. As a part of the WTO Agreements, 
TRIPS is subject to WTO’s dispute mechanism, which allows member states to apply trade 
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sanctions against non-compliant countries. This has placed unnecessary pressure on the 
developing countries to adopt IPR legislation that is not at all suitable to their developing 
economies or the health and needs of their people. Developing countries fear that if they do not 
follow the TRIPS agreement and choose instead to alternately design legislation in support their 
own development needs, then they will be sanctioned by developed countries, a nightmarish 
possibility. 
4.4.1 TRIPS and Pharmaceuticals 
With respect to pharmaceuticals, there are provisions of TRIPS that are particularly 
detrimental to the pharmaceutical industries of developing countries, greatly impeding access to 
essential medicines in the developing world. These provisions include the following: 
• All countries have to accept patents on all inventions provided they are “non-
obvious” and have “industrial applicability” without discrimination to the place of 
invention, the field of technology or whether the protected product is locally 
produced or imported. 
• Developing countries have to provide 20-years patent protection to 
pharmaceutical products and processes. 
• Patent holders will not be obliged to work the patent by setting up production 
facilities to manufacture product in the product granting country, rather they can 
force the country to import the product and still hold the monopoly. 
The first provision is “ a clear expression of the search by industrialized countries for a 
legal system that facilitates international trade rather than local workings of inventions” (Correa, 
2006). Developing countries need the freedom to decide upon patent regulation to meet their 
individual stage of development, and forcing them to protect all patents greatly impedes the 
growth of their own industries. As stated previously, the developed countries of today with the 
strongest pharmaceutical industries did not protect product patents of pharmaceuticals until the 
late 60’s and 70’s, allowing their companies to find alternate routes to manufacture needed 
drugs. This control over their own productive development served to strengthen research 
capabilities while simultaneously providing access to needed medications for their citizens. 
However, now under TRIPs, developing countries are not free to make this decision, and their 
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pharmaceutical industries as well as the majority of their populations are suffering greatly as a 
result. 
Unfortunately, a 20-years patent protection greatly limits access to a majority of 
medications the majority of medications that are needed immediately, and they might be useless 
to the population after 20-years of further R&D and or mutations of viruses and evolution of 
diseases. Further, holding 20-years of patent protection is excessive as the return of investment is 
usually achieved within the first five years, and any additional revenue is funneled into net profit 
and marketing. This 20-year patent provision means that countries cannot begin to produce 
generic versions of a drug until after 20-years, which gives the patent holder a monopoly over 
the drug and the ability to charge the maximum the market can bear. This greatly limits the 
affordability and availability of many essential medications, and in turn results in the 
unnecessary death of millions a year. 
Moreover, before the TRIPs agreement a patent was considered null if it was not 
produced in the country holding the patent. In other words, if Pfizer held a patent on a specific 
drug in South Africa, the company was required to produce the drug in South Africa to maintain 
the patent rights, and if it failed to do so then South Africa could produce generic versions on its 
own. Under TRIPs however, companies are not required to manufacture their drugs in all 
countries where it has obtained patents, rather importation of the drug to each country will 
suffice for proper “working of the patent”.   
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5 IMPACT OF TRIPS ON THE DEVELOPING WORLD 
 
  The impact of IPRs on developing countries is extremely difficult to assess due to the 
wide variety of economic and institutional factors contributing to development at all levels of the 
developing world. However, although it is difficult to isolate the impact of IPR, it is possible to 
analyze various areas of development in which IPR plays a crucial role and explore changes in 
these areas since the introduction of the TRIPS agreement. Specifically, in order to achieve 
economic development it is necessary to develop indigenous technological capability, and many 
multinationals claim that increased IPR protection in developing countries will serve to increase 
technology transfer, foreign direct investment (FDI), and exports, which are debatably believed 
to be the roots of technological development. However, further analysis reveals the fallacy of this 
claim. With specific regard to pharmaceutical industries, the effect of IPRs through TRIPS has 
been detrimental to the development of pharmaceutical manufacturing and research capabilities 
in developing countries, and has lead to the collapse of many of the developing world’s leading 
affordable medicine manufacturers.  
5.1 Indigenous Technological Capability 
 In order to improve the economy of developing countries and reduce poverty, it is 
imperative that these countries develop indigenous technological capacity like the developed 
countries before them. As explored in 2002 by the UK Commission on Intellectual Property 
Rights, the development of this indigenous technological capacity determines the ability of these 
countries to assimilate and apply foreign technology and is therefore the key factor in achieving 
successful technology transfer. In order to achieve successful economic development, developing 
countries need technology transfer from more developed countries so they can imitate the 
technology and build their own technological capacity.  However developing countries have 
different levels of quality and capacity in their technological and scientific infrastructures. 
Therefore, the question is not so much whether IPR increases trade or foreign investment in 
developing countries, but rather the effect it has on their ability to obtain and assimilate 
technologies necessary for their development. 
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 In order to assess the indigenous technological capability of developing countries, one 
can assess the patenting activity in the US and internationally through the Patent Cooperation 
Treaty (PCT). A country with decent indigenous technological capability should also have a 
substantial innovative research base, and therefore should have a number of international patent 
applications. In 2001, less than 1% of US Patents were granted to developing countries, and 
nearly 60% of those were granted to seven of the more technologically advanced developing 
countries. From 1999-2001, within the PCT fewer than 2% of all patent applications were from 
developing countries, and 95% of those were from the more technologically developed China, 
India, South Africa, Brazil, and Mexico (UK Commission, 2002). As can be observed, the 
technological capacity of most developing countries is very limited, a point that is also reflected 
in the pharmaceutical research and development markets as discussed previously. Research and 
Development expenditure is very concentrated in developed countries and a handful of stronger 
developing countries, proving the lack of sufficient capacity within the developing world to 
obtain and assimilate technology from developed countries for further development of their own 
indigenous capacity. 
5.1.1 Transfer of Technology 
 As explored by the UK Commission on IPR, the transfer of technology needed to develop 
indigenous technological capacity in developing countries must be sustainable. The Commission 
identifies “ the crucial issue in respect of IP is not whether it promotes trade or foreign 
investment, but how it helps or hinders developing countries to gain access to technologies that 
are required for their development”. As an example, licensing a foreign technology to a domestic 
firm in a developing country will serve to enrich the local economy by building technological 
understanding and infrastructure. In contrast, importing high technology goods will not 
necessarily help the underdeveloped economy, as it will not have the technological ability to 
dissect the new technology for understanding and promotion of new innovation. In the past, low 
levels of IPR were used by today’s technological leaders to allow them access to foreign 
technology that they then developed through reverse engineering to build indigenous 
technological capabilities.  
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5.1.2 Foreign Investment 
Although developed countries and their affiliates claim that stronger IPRs will result in 
greater FDI to developing countries, many studies have shown that there is little correlation 
between IPRs and FDI (Noges, 1991). The World Bank Zedillo Report on financing for 
development makes no mention of IPRs, and the majority of industries likewise omit IPRs when 
determining factors important for foreign investment. As examples, East Asia and Latin 
American economies with high growth rates have received the bulk of FDI even though they 
have weak IPRs. Specifically, China, Singapore, Malaysia, Hong Kong, and Indonesia in 1991 
accounted for 90% of FDI flows in the Asia Pacific Region even with considerably weak IPR 
legislation that did not come close to the currently minimum standards under TRIPS (Correa, 
2000). Overall, the “foreign direct investment by US firms is largely devoted to sales and 
distribution outlets and rudimentary production and assembly facilities, a country’s intellectual 
property rights protection will have little effect on the total amount invested by US firms” 
(Mansfield, 1994).  
5.1.3 Export Increase 
Developed countries also claim that stronger IPR protection will result in greater 
investment with respect to more sophisticated technologies if a country has the scientific 
capacity and a sufficient market needed to justify cost of patents. However, even under those 
circumstances, IPR has lead to greater imports instead of the anticipated investment and boost in 
local production. According to a statement issued by the UN in 1993, innovative companies in 
the developed world are more apt to directly sell products or services rather than transfer 
technology through FDI or licensing agreements, which results in an increase in exports to 
developing countries from developed countries, and a decrease in needed technology transfer. 
This is observed in a study done by Helpman and Krugman at the University of Deleware that 
found a correlation between an increase in exports from the US in 1992 and the strengthening of 
IPRs in importing countries (Smith, 1995). Furthermore, another study done by Maskus in 2000 
reveals “that if an average developing country were to strengthen its patent index by one unit, 
local sales on US affiliates would rise by about 2% of average annual sales… and a one-unit 
increase in the patent index of the average developing economy would raise the asset stock on 
US multinational affiliates by… about 16% of average annual stock.” (Maskus, 2000) In 
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addition, “the value of exports form high income countries after the introduction of TRIPS in 
1995 grew from 20 billion to over 80 billion in 1999.” (Balasubramaniam, 2002) 
 With specific respect to the pharmaceutical industry, FDI in Brazil’s pharmaceutical 
industry surpassed all other FDI once protection for medicines was abolished. In addition, FDI in 
Turkey’s pharmaceutical manufacturing industry was the largest of all other manufacturing 
industries after Turkey eliminated patent protection for pharmaceutical products in 1961 (UN, 
1993). In contrast, a study by WB economist Nogues in 1990 reveals that as a result of increased 
patent protection, the welfare loss to six developing countries (Argentina, Brazil, India, Mexico, 
Korea, Taiwan) was at minimum US $3.5 billion and maximum US $10.8billion, while the gain 
to foreign patent holders was from US $2.1 billion to US $14.4 billion. The disparity between the 
growth of pharmaceutical sales in developed countries and that of the developing world has only 
increased since this study, as can be observed in Figure 9 where data gathered from the IMS 
Pharmaceutical consultation documents was used to assess the growth of the world’s 
pharmaceutical industries. The total global pharmaceutical market has grown from 
approximately $300 billion in 1998 to over $600 billion in 2006, and over 50% of the current 
market is controlled by North America (IMS, 2006). It is obvious from this data that as a result 
of stronger IPR protection the exports and sales of the developed countries’ pharmaceutical 
products have grown substantially while the markets of the developing countries have remained 
stagnant.  
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Figure 9: Growth of Pharmaceutical Sales by Region
11
 
5.2 Impact on Pharmaceutical Prices 
 Universal IPR legislation creates a monopoly on pharmaceuticals through patent 
protection that removes generic competition. This results in high prices which reflect the 
maximum the market can bear to maximize profits; a common practice in the developed world. 
An uncontested set of studies done within developed and developing countries by the WB & 
IMF clearly indicate price increases on pharmaceuticals as a result of increased IPR. “The 
existence of a patent allows, by the very nature of the rights conferred, isolation of a product 
from price based competition, and the question at stake is the quantum rather than the existence 
of that increase” (Correa, 2000).  
 To illustrate the disparity between pharmaceutical prices in different countries with 
different IPR regulations, Figure 10 Compares the prices on top medicines in 1997, and Table 5 
the price ratios of drugs under different patent status in developing and developed countries. 
Both figures reveal the substantial difference in drug prices between countries with various 
levels of IPR legislation.  
 
                                                
11 IMS World Review (2000). 
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Figure 10 Comparisons of Prices on Top Medicines (1997)
12
 
 
 
 
                                                
12 B.K. Keayla. TRIPS Agreement on Patent Laws: Impact on Pharmaceuticals and Health for 
All (1997). 
13 K Bala, K Sagoo, Patents and Prices. HAINEWS No 112, April/May (2000). 
Range of Ratios Between Lowest and Highest Retail Prices of 100 
Units of Selected Drugs 
OECD Developing Countries 
Patent Status 
No of Dosage 
Forms 
Range of Ratios No of Dosage 
Forms 
Range of Ratios 
Drugs Protected 
by Patents 
8 1:1.7 – 1:1.2 6 1:1.2 - 1:4 
Multi-source 
Drugs 
13 1.2 - 1:11.5 17  
 
1:1.7 – 1:59 
Table 5 Price Ratios of Drugs Under Different Patent Status in Developed and Developing 
Countries
13
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5.3 Case Studies 
 An investigation into the impact of IPR on pharmaceutical production in developing 
countries can be observed through the industries of South Africa and India. While the IPR 
legislation in South Africa practically destroyed its manufacturing capability, the decision in 
India to not protect product patents on pharmaceuticals has lead to a substantial growth of 
pharmaceutical industries, and after two decades has produced the lowest price of 
pharmaceuticals in the world. 
5.3.1 South Africa: 39 Manufacturers vs. the SA Government 
 In the late 1990’s there was over eighty pharmaceutical manufacturers in Sub-Saharan 
Africa. In 1997 South Africa amended its patent legislation to comply with TRIPS, and the 
manufacturers fought back with a court case against the government, which the latter dropped in 
2001 after great pressures. After numerous mergers and great restrictions on manufacturing 
following adoption of TRIPS, many manufacturing companies were forced to close. There are 
currently only 14 pharmaceutical manufacturers remaining to produce ARV treatments in South 
Africa (Intellectual Property Watch, 2006).  
5.3.2 India: No Product Protection Needed for Pharmaceutical Growth 
 As a former British colony, India’s patent law in the 1950’s and 60’s reflected UK 
legislation that protected product patents on pharmaceuticals, and as a result India had some of 
the highest drug prices in the world. In the 60’s India realized that patent laws were blocking the 
growth of its pharmaceutical industry, and the former British colony adapted its patent law to 
mirror German legislation. Specifically, they decided to grant process patents for 7-10 years, 
they excluded pharmaceutical products from protection, they obliged the title-holder to work the 
patent, and they made provisions for compulsory licenses. India quickly developed itself as a 
world leader in generic manufacturing, and simultaneously developed its research and innovative 
base with a growth of over 200 000 pharmaceutical companies. Within 2 years, drug prices in 
India became the lowest in the world, sometimes up to 41 percent cheaper than the multinational 
price. 
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6 CONCLUSION: WHAT CAN BE DONE 
 Global IP systems must be reviewed and restructured to aid in the development of poor 
countries through the stimulation of technology transfer and innovation while simultaneously 
providing products at affordable prices, most notably medicines. With the current TRIPS 
legislation, public health in the developing world faces a gigantic barrier that will not be easy for 
countries just beginning industrial growth to overcome. While the removal of TRIPS from the 
WTO would be the best solution, it is not likely to happen as long as the developed countries 
control the WTO. Therefore, developing countries must take advantage of the safeguards 
currently available under TRIPS, and it is imperative that they develop their own legislations to 
create as many opportunities possible to pursue development interests and meet public health 
needs.  
6.1 Legislation in Developing World 
 Although it is established that health within the developing world is being severely 
damaged by the TRIPs agreement, there are some provisions within the agreement that may be 
used to obtain medications needed to treat at least a fraction of the millions worldwide that are in 
desperate need of such products. These provisions include the principle of exhaustion of rights 
(otherwise referred to as parallel importation), compulsory licensing, and the “bolar provision”. 
However, a major problem in developing countries is the lack of adequate intellectual property 
legal force, and when the knowledge of IPR issues and legislation is lacking in a country, it is 
virtually impossible to navigate to around the congested TRIPs agreement. Therefore, it is 
necessary for developing countries to strengthen their knowledge of IP Law, and their legal 
infrastructure and legislative process to deal with IPR issues. 
6.1.1 Parallel Imports 
 Primarily, the principal of exhaustion of rights refers to the termination of rights given to 
an inventor with the granting of a patent. The provision states that an inventor relinquishes his 
right to the given product as soon as he sells the product to another. In other words, once a 
patented product is sold, it can then be re-sold without royalty paid to or consent from the 
original patent holder. Exhaustion of rights can also be extended to parallel importation, where a 
product sold for a low price by country X to country Y may be bought by country Z for the same 
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low price paid by Y, preventing country X from charging country Z full market price for the 
product. This is especially important with pharmaceuticals, as some developing countries pay 
considerably lower prices for certain medications than other countries, and therefore if this 
provision is properly instituted, other developing nations can legally import the needed 
medications at the lowest offered price without consulting the original manufacturer.  
6.1.2 Compulsory Licensing 
 When a country is able to prove an imperative need for a product, there is a provision for 
compulsory licenses which may be instituted that allows the country to bypass the IPRs on that 
product and produce a generic version of the needed drug. A compulsory license is granted by 
the country in need, provided its national legislation accounts for the provision, and does not 
need to be approved by outside parties. However, due to the limited IPR council in developing 
countries, it is difficult for most countries to sort their way through the legal jargon and adapt 
their legislation to provide for these compulsory licenses. To date the provision has been used 
more as a bargaining tool with pharmaceutical companies then a method to gain access to needed 
medications. 
For any of the following reasons a country may issue compulsory licenses: 
• Dependency of patents, that is, another invention requires the use of the patent in 
question to exercise the right of the new invention 
• Government or non-governmental use 
• Cases of national emergency 
• Remedy against anti-competitive practices 
• Reasons of public health 
• Protection of environment 
 
Further, the following conditions must be met before a license may be granted:  
• Must be non-exclusive 
• Case-by-case consideration 
• Possibility for revocation of compulsory license if circumstances that motivated granting 
of license disappears 
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• Refusal by the title holder of a prior offer by the prospective user made on reasonable 
commercial terms 
• Adequate remuneration paid to the title holder 
When granting compulsory licenses, it is entirely up to the country using the compulsory license 
to define the scope of “reasonable commercial terms” and “adequate remuneration” for patent 
holder approval, however those terms must be approved by the title holder. 
 Included within that list is a provision for “reasons of public health”, which was designed 
to ensure that TRIPS does not have the negative effect on public health, as widely feared. It is 
meant to encompass all threats to public health and should therefore theoretically be used by all 
countries to gain access to needed medications. In addition, the government and non-
governmental use provision should theoretically be easy for governments to justify given the 
current state of the world’s poor. However, to repeat an important consideration, as the legal 
know-how needed to empower these provisions is quite complicated and has been designed by 
experts in the field from industrialized countries, it is extremely difficult for developing countries 
to work towards these provisions for fear that if they make a legal mistake they will incur the 
reprimand of the WTO and/or hurt their bilateral trade agreements with the developed world. If 
these provisions were truly designed to ease the state of the world’s suffering, they would be 
used often all over the world, and the necessary infrastructural support needed by developing 
countries would be more easily acquired from the more industrialized nations. The simple fact 
that they are rarely used proves their insufficient nature.  
6.1.3 Bolar Provision 
 The “bolar provision” was established in Canada and allows for the testing and regulatory 
approval of a generic version of a drug before the patent of that drug expires. This allows the 
necessary development and registration of generic versions of the drug to be completed before 
the end of the patent allowing the generic manufacturer to begin sale of the drug as soon as its 
patent expires. This greatly facilitates generic competition, and provides more immediate access 
to needed medications at affordable prices (WHO, 2006).  
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6.1.2 Infrastructure 
 The majority of developing countries do not have a proper patent application revision 
processes, and a large number of patents that pass through their systems should in actuality not 
be accepted. Many applications received claim trivial or generically determined processes, 
second uses of known products, or formulations of products already in the market. Although 
TRIPS states that “all patents shall be granted to protect inventions that are new, involve an 
inventive step, and are capable of industrial application”, these specific requirements are not 
defined, and each country is allowed to determine the scope of each definition. While the term 
“invention” generally refers to a developed solution to a problem through the use of 
technological application, it would be beneficial for developing countries to cater their individual 
legislation to their special circumstances, thus allowing more freedom for local innovations. For 
example, when it comes to biological related patents, in order to protect traditional medicines 
and biodiversity it is possible to follow a definition of invention that broadly excludes material 
pre-existing in nature (Correa, 2000).  
6.2 The Prospect of Bangladesh 
 In 2001, after substantial pressure and lobbying by public health activists, the Doha 
Declaration was enacted to ensure that TRIPS would not act as a barrier to access to medicines in 
the developing world. The Doha Declaration provided an extension to 2005 for Developing 
Countries to meet the minimum TRIPS requirements, and an extension to 2016 for the Least 
Developed Countries. However, now in 2006 the world’s major generic drug manufacturers for 
the developing world, India and China are following TRIPS regulation and can no longer 
produce generic versions of new foreign drugs. As the main suppliers of essential medications to 
the developing world, this new restriction on pharmaceutical production will be detrimental to 
the health of the world’s population. Although LDC’s were granted an extension until 2016 to 
meet TRIPS compliance, the only LDC with pharmaceutical manufacturing capability is 
Bangladesh, which is currently under pressure from trade agreements to adopt TRIPS compliant 
IPR legislation. If Bangladesh resists the trade pressures and chooses to revise its patent 
legislation to exclude product patents on pharmaceuticals, it can potentially become the major 
generic manufacturer for the developing world. This would not only serve to boost its economy, 
but it would also serve to strengthen its research base and innovative capability while 
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simultaneously providing essential medications at affordable prices to the world’s most desperate 
citizens. 
6.3 Pharmaceutical Industry Development 
 In order to meet the health needs of the developing world it is imperative that 
pharmaceutical capability is established within their boarders. Eleven years after TRIPS, it is 
obvious that the developed world is not going to invest in research and development on diseases 
that affect the world’s poor because there would be little financial return. In addition, TRIPS has 
had a detrimental impact on the pharmaceutical capabilities of the developing world and will 
continue to curb innovation and development of industries there until it is abolished, or at least 
revised to exclude pharmaceutical products. If this is not done, then the pharmaceutical 
industries of the world’s developing countries will continue to founder under TRIPS, and they 
will never be able to establish their own research and innovation capabilities to meet their 
desperate health needs.  
 Pharmaceutical companies within developing countries, namely India and China, can no 
longer produce generics of new foreign drugs and threaten to follow the same deteriorating path 
of those in South Africa at the end of the 90’s. In order to stay afloat, the governments of these 
countries should encourage and support these companies to pursue the manufacturing of 
chemical intermediates that may be marketed to other countries, including Bangladesh, which 
will serve to maintain the survival of the pharmaceutical infrastructure until the TRIPS issue is 
resolved. Although not a long term solution, shifting focus from generic production to the 
production of chemical intermediates will help boost the research base and innovative capacity 
of the stagnant industries, and might tide the industries over long enough until more drugs come 
off patent and become available to the generic market. 
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Appendix A:  Intellectual Property Legislation 
A.1.Paris Convention 
 
http://beta.austlii.edu.au/au/other/dfat/treaties/1972/12.html 
 
PARIS CONVENTION FOR THE PROTECTION OF INDUSTRIAL PROPERTY OF 20 
MARCH 1883, AS REVISED AT BRUSSELS ON 14 DECEMBER 1900, AT 
WASHINGTON ON 2 JUNE 1911, AT THE HAGUE ON 6 NOVEMBER 1925, AT 
LONDON ON 2 JUNE 1934, AT LISBON ON 31 OCTOBER 1958, AND AT 
STOCKHOLM ON 14 JULY 1967 
Article 1 
[Establishment of the Union; scope of industrial property] 
 
 (1) The countries to which this Convention applies constitute a Union for the protection of 
industrial property. 
(2) The protection of industrial property has as its object patents, utility models, industrial 
designs, trademarks, service marks, trade names, indications of source or appellations of 
origin, and the repression of unfair competition. 
(3) Industrial property shall be understood in the broadest sense and shall apply not only to 
industry and commerce proper, but likewise to agricultural and extractive industries and to all 
manufactured or natural products, for example, wines, grain, tobacco leaf, fruit, cattle, 
minerals, mineral waters, beer, flowers, and flour. 
(4) Patents shall include the various kinds of industrial patents recognized by the laws of the 
countries of the Union, such as patents of importation, patents of improvement, patents and 
certificates of addition, etc. 
 
 
Article 2 
[National treatment for nationals of countries of the Union] 
 
(1) Nationals of any country of the Union shall, as regards the protection of industrial property, 
enjoy in all the other countries of the Union the advantages that their respective laws now 
grant, or may hereafter grant, to nationals; all without prejudice to the rights specially 
provided for by this Convention. Consequently, they shall have the same protection as the 
latter, and the same legal remedy against any infringement of their rights, provided that the 
conditions and formalities imposed upon nationals are complied with. 
(2) However, no requirement as to domicile or establishment in the country where protection is 
claimed may be imposed upon nationals of countries of the Union for the enjoyment of any 
industrial property rights. 
(3) The provisions of the laws of each of the countries of the Union relating to judicial and 
administrative procedure and to jurisdiction, and to the designation of an address for service 
or the appointment of an agent, which may be required by the laws on industrial property be 
expressly reserved. 
 
 56 
 
 
Article 3 
[Same treatment for certain categories of persons as for nationals of countries of the Union] 
Nationals of countries outside the Union who are domiciled or who have real and effective 
industrial or commercial establishments in the territory of one of the countries of the Union shall 
be treated in the same manner as nationals of the countries of the Union. 
Article 4 
[A to I. Patents, utility models, industrial designs, marks, inventors’ certificates: right of 
priority. - G. Patents: division of the application] 
A. (1) Any person who has duly filed an application for a patent, or for the registration of a 
utility model, or of an industrial design, or of a trademark, in one of the countries of the 
Union, or his successor in title, shall enjoy, for the purpose of filing in the other 
countries, a right of priority during the periods hereinafter fixed. 
 
(2) Any filing that is equivalent to a regular national filing under the domestic 
legislation of any country of the Union or under bilateral or multilateral treaties 
concluded between countries of the Union shall be recognized as giving rise to the 
right of priority. 
(3) By a regular national filing is meant any filing that is adequate to establish the date on which 
the application was filed in the country concerned, whatever may be the subsequent fate of 
the application. 
 
B. Consequently, any subsequent filing in any of the other countries of the Union before the 
expiration of the periods referred to above shall not be invalidated by reason of any acts 
accomplished in the interval, in particular, another filing, the publication or exploitation 
of the invention, the putting on sale of copies of the design, or the use of the mark, and 
such acts cannot give rise to any third-party right or any right of personal possession. 
Rights acquired by third parties before the date of the first application that serves as the 
basis for the right of priority are reserved in accordance with the domestic legislation of 
each country of the Union. 
C. (1) The periods of priority referred to above shall be twelve months for patents and utility 
models, and six months for industrial designs and trademarks. 
 
(2) These periods shall start from the date of filing of the first application; the day of 
filing shall not be included in the period. 
(3) If the last day of the period is an official holiday, or a day when the Office is not open for the 
filing of applications in the country where protection is claimed, the period shall be extended 
until the first following working day. 
(4) A subsequent application concerning the same subject as a previous first application within 
the meaning of paragraph (2), above, filed in the same country of the Union, shall be 
considered as the first application, of which the filing date shall be the starting point of the 
period of priority, if, at the time of filing the subsequent application, the said previous 
application has been withdrawn, abandoned, or refused, without having been laid open to 
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public inspection and without leaving any rights outstanding, and if it has not yet served as a 
basis for claiming a right of priority. The previous application may not thereafter serve as a 
basis for claiming a right of priority. 
 
D. (1) Any person desiring to take advantage of the priority of a previous filing shall be 
required to make a declaration indicating the date of such filing and the country in which 
it was made. Each country shall determine the latest date on which such declaration must 
be made. 
 
(2) These particulars shall be mentioned in the publications issued by the competent 
authority, and in particular in the patents and the specifications relating thereto. 
(3) The countries of the Union may require any person making a declaration of priority to 
produce a copy of the application (description, drawings, etc.) previously filed. The 
copy, certified as correct by the authority which received such application, shall not 
require any authentication, and may in any case be filed, without fee, at any time 
within three months of the filing of the subsequent application. They may require it to 
be accompanied by a certificate from the same authority showing the date of filing, 
and by a translation. 
(4) No other formalities may be required for the declaration of priority at the time of 
filing the application. Each country of the Union shall determine the consequences of 
failure to comply with the formalities prescribed by this Article, but such 
consequences shall in no case go beyond the loss of the right of priority. 
(5) Subsequently, further proof may be required. 
 
Any person who avails himself of the priority of a previous application shall be required to 
specify the number of that application; this number shall be published as provided for by 
paragraph (2), above. 
E. (1) Where an industrial design is filed in a country by virtue of a right of priority based 
on the filing of a utility model, the period of priority shall be the same as that fixed for 
industrial designs. 
 
(2) Furthermore, it is permissible to file a utility model in a country by virtue of a 
right of priority based on the filing of a patent application, and vice versa. 
F. No country of the Union may refuse a priority or a patent application on the ground that 
the applicant claims multiple priorities, even if they originate in different countries, or on 
the ground that an application claiming one or more priorities contains one or more 
elements that were not included in the application or applications whose priority is 
claimed, provided that, in both cases, there is unity of invention within the meaning of the 
law of the country. 
 
With respect to the elements not included in the application or applications whose 
priority is claimed, the filing of the subsequent application shall give rise to a right 
of priority under ordinary conditions. 
G. (1) If the examination reveals that an application for a patent contains more than one 
invention, the applicant may divide the application into a certain number of divisional 
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applications and preserve as the date of each the date of the initial application and the 
benefit of the right of priority, if any. 
 
(2) The applicant may also, on his own initiative, divide a patent application and 
preserve as the date of each divisional application the date of the initial application 
and the benefit of the right of priority, if any. Each country of the Union shall have 
the right to determine the conditions under which such division shall be authorized. 
H. Priority may not be refused on the ground that certain elements of the invention for which 
priority is claimed do not appear among the claims formulated in the application in the 
country of origin, provided that the application documents as a whole specifically 
disclose such elements. 
I. (1) Applications for inventors’ certificates filed in a country in which applicants have the 
right to apply at their own option either for a patent or for an inventor’s certificate shall 
give rise to the right of priority provided for by this Article, under the same conditions 
and with the same effects as applications for patents. 
 
(2) In a country in which applicants have the right to apply at their own option 
either for a patent or for an inventor’s certificate, an applicant for an inventor’s 
certificate shall, in accordance with the provisions of this Article relating to patent 
applications, enjoy a right of priority based on an application for a patent, a utility 
model, or an inventor’s certificate. 
Article 4bis 
[Patents: independence of patents obtained for the same invention in different countries] 
(1) Patents applied for in the various countries of the Union by nationals of countries of the 
Union shall be independent of patents obtained for the same invention in other countries, 
whether members of the Union or not. 
(2) The foregoing provision is to be understood in an unrestricted sense, in particular, in the 
sense that patents applied for during the period of priority are independent, both as regards 
the grounds for nullity and forfeiture, and as regards their normal duration. 
(3) The provision shall apply to all patents existing at the time when it comes into effect. 
(4) Similarly, it shall apply, in the case of the accession of new countries, to patents in existence 
on either side at the time of accession. 
(5) Patents obtained with the benefit of priority shall, in the various countries of the Union, have 
a duration equal to that which they would have, had they been applied for or granted without 
the benefit of priority. 
 
 
Article 4ter 
[Patents: Mention of the inventor in the patent] 
 
The inventor shall have the right to be mentioned as such in the patent. 
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Article 4quater 
[Patents: patentability in case of restrictions of sale by law] 
 
The grant of a patent shall not be refused and a patent shall not be invalidated on the 
ground that the sale of the patented product or of a product obtained by means of a 
patented process is subject to restrictions or limitations resulting from the domestic law. 
 
Article 5 
[A. Patents: importation of articles; failure to work or insufficient working; compulsory 
licenses. B. Industrial designs: failure to work; importation of articles. C. Marks: failure to 
use; different forms; use by co-proprietors. D. Patents, utility models, marks, industrial 
designs: marking] 
A. (1) Importation by the patentee into the country where the patent has been granted of articles 
manufactured in any of the countries of the Union shall not entail forfeiture of the patent. 
 
(2) Each country of the Union shall have the right to take legislative measures providing for 
the grant of compulsory licenses to prevent the abuses which might result from the 
exercise of the exclusive rights conferred by the patent, for example, failure to work. 
(3) Forfeiture of the patent shall not be provided for except in cases where the grant of 
compulsory licenses would not have been sufficient to prevent the said abuses. No 
proceedings for the forfeiture or revocation of a patent may be instituted before the 
expiration of two years from the grant of the first compulsory license. 
(4) A compulsory license may not be applied for on the ground of failure to work or 
insufficient working before the expiration of a period of four years from the date of filing 
of the patent application or three years from the date of the grant of the patent, whichever 
period expires last; it shall be refused if the patentee justifies his inaction by legitimate 
reasons. Such a compulsory licence shall be non-exclusive and shall not be transferable, 
even in the form of the grant of a sub-license, except with that part of the enterprise or 
goodwill which exploits such license. 
(5) The foregoing provisions shall be applicable, mutatis mutandis, to utility models. 
 
B. The protection of industrial designs shall not, under any circumstance, be subject to any 
forfeiture, either by reason of failure to work or by reason of the importation of articles 
corresponding to those which are protected. 
C. (1) If, in any country, use of the registered mark is compulsory, the registration may be 
cancelled only after a reasonable period, and then only if the person concerned does not 
justify his inaction. 
 
(2) Us of a trademark by the proprietor in a form differing in elements which do not alter the 
distinctive character of the mark in the form in which it was registered in one of the 
countries of the Union shall not entail invalidation of the registration and shall not 
diminish the protection granted to the mark. 
(3) Concurrent use of the same mark on identical or similar goods by industrial or 
commercial establishments considered as co-proprietors of the mark according to the 
provisions of the domestic law of the country where protection is claimed shall not 
prevent registration or diminish in any way the protection granted to the said mark in any 
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country of the Union, provided that such use does not result in misleading the public and 
is not contrary to the public interest. 
 
D. No indication or mention of the patent, of the utility model, of the registration of the 
trademark, or of the deposit of the industrial design, shall be required upon the goods as a 
condition of recognition of the right to protection. 
 
 
Article 5bis 
[All industrial property rights: period of grace for the payment of fees for the maintenance 
of rights; patents: restoration] 
(1) A period of grace of not less than six months shall be allowed for the payment of the fees 
prescribed for the maintenance of industrial property rights, subject, if the domestic 
legislation so provides, to the payment of a surcharge. 
(2) The countries of the Union shall have the right to provide for the restoration of patents which 
have lapsed by reason of non-payment of fees. 
 
 
Article 5ter 
[Patents: patented devices forming part of vessels, aircraft, or land vehicles] 
 
In any country of the Union the following shall not be considered as infringements of the 
rights of a patentee: 
1. the use on board vessels of other countries of the Union of devices forming the subject of his 
patent in the body of the vessel, in the machinery, tackle, gear and other accessories, when 
such vessel temporarily or accidentally enter the waters of the said country, provided that 
such devices are used there exclusively for the needs of the vessel; 
2. the use of devices forming the subject of the patent in the construction or operation of aircraft 
or land vehicles of other countries of the Union, or of accessories of such aircraft or land 
vehicles, when those aircraft or land vehicles temporarily or accidentally enter the said 
country. 
 
 
Article 5quater 
[Patents: importation of products manufactured by a process patented in the importing 
country] 
When a product is imported into a country of the Union where there exists a patent protecting a 
process of manufacture of the said product, the patentee shall have all the rights, with regard to 
the imported product, that are accorded to him by the legislation of the country of importation, 
on the basis of the process patent with respect to products manufactured in that country. 
Article 5quinquies 
[Industrial designs] 
 
Industrial designs shall be protected in all the countries of the Union. 
 
 61 
Article 6 
[Marks: conditions of registration; independence of protection of same mark in different 
countries] 
(1) The conditions for the filing and registration of trademarks shall be determined in each 
country of the Union by its domestic legislation. 
(2) However, an application for the registration of a mark filed by a national of a country of the 
Union in any country of the Union may not be refused, nor may a registration be invalidated, 
on the ground that filing, registration, or renewal, has not been effected in the country of 
origin. 
(3) A mark duly registered in a country of the Union shall be regarded as independent of marks 
registered in the other countries of the Union, including the country of origin. 
 
 
Article 10 
[False indications: seizure, on importation, etc, of goods bearing false indications as to their 
source or the identity of the producer] 
(1) The provisions of the preceding Article shall apply in cases of direct or indirect use of a false 
indication of the source of the goods or the identity of the producer, manufacturer, or 
merchant. 
(2) Any producer, manufacturer, or merchant, whether a natural person or a legal entity, engaged 
in the production or manufacture of or trade in such goods and established either in the 
locality falsely indicated as the source, or in the region where such locality is situated, or in 
the country falsely indicated, or in the country where the false indication of source is used, 
shall in any case be deemed an interested party. 
 
 
Article 10bis 
[Unfair competition] 
 
(1) The countries of the Union are bound to assure to nationals of such countries effective 
protection against unfair competition. 
(2) Any act of competition contrary to honest practices in industrial or commercial matters 
constitutes an act of unfair competition. 
(3) The following in particular shall be prohibited: 
 
1. all acts of such a nature as to create confusion by any means whatever with the 
establishment, the goods or the industrial or commercial activities, of a competitor; 
2. false allegations in the course of trade of such a nature as to discredit the establishment, 
the goods, or the industrial or commercial activities, of a competitor; 
3. indications or allegations the use of which in the course of trade is liable to mislead the 
public as to the nature, the manufacturing process, the characteristics, the suitability for 
their purpose, or the quantity, of the goods. 
 
 
Article 10ter 
[Marks, trade names, false indications, Unfair competition: remedies, right to sue] 
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(1) The countries of the Union undertake to assure to nationals of the other countries of the 
Union appropriate legal remedies effectively to repress all the acts referred to in Articles 9, 
10, and 10bis. 
(2) They undertake, further, to provide measures to permit federations and associations 
representing interested industrialists, producers, or merchants, provided that the existence of such 
federations and associations is not contrary to the laws of their countries, to take action in the 
courts or before the administrative authorities, with a view to the repression of the acts referred 
to in Articles 9, 10, and 10bis, in so far as the law of the country in which protection is claimed 
allows such action by federations and associations of that country. 
 
Article 11 
[Inventions, utility models, industrial designs, marks: temporary protection at certain 
international exhibitions] 
(1) The countries of the Union shall, in conformity with their domestic legislation, grant 
temporary protection to patentable inventions, utility models, industrial designs, and 
trademarks, in respect of goods exhibited at official or officially recognized international 
exhibitions held in the territory of any of them. 
(2) Such temporary protection shall not extend the periods provided by Article 4. If, later, the 
right of priority is invoked, the authorities of any country may provide that the period shall 
start from the date of introduction of the goods into the exhibition. 
(3) Each country may require, as proof of the identity of the article exhibited and of the date of 
its introduction, such documentary evidence as it considers necessary. 
 
 
Article 12 
[Special national industrial property services] 
 
(1) Each country of the Union undertakes to establish a special industrial property service and a 
central office for the communication to the public of patents, utility models, industrial 
designs, and trademarks. 
(2) This service shall publish an official periodical journal. It shall publish regularly: 
 
(a) the names of the proprietors of patents granted, with a brief designation of the inventions 
patented; 
(b) the reproductions of registered trademarks. 
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A.2. Trade Related Aspects of Intellectual Property Rights (TRIPS) 
 
http://www.wto.org/english/tratop_e/trips_e/t_agm3c_e.htm#5 
 
ANNEX 1C OF THE MARRAKESH AGREEMENT ESTABLISHING THE WORLD 
TRADE ORGANIZATION, SIGNED IN MARRAKESH, MOROCCO ON 15
TH
 APRIL 
1994 
 
PART II — STANDARDS CONCERNING THE AVAILABILITY, SCOPE AND USE OF 
INTELLECTUAL PROPERTY RIGHTS 
 
 
Article 27 [Patentable Subject Matter] 
1. Subject to the provisions of paragraphs 2 and 3, patents shall be available for any inventions, 
whether products or processes, in all fields of technology, provided that they are new, involve an 
inventive step and are capable of industrial application. (1) Subject to paragraph 4 of Article 65, 
paragraph 8 of Article 70 and paragraph 3 of this Article, patents shall be available and patent 
rights enjoyable without discrimination as to the place of invention, the field of technology and 
whether products are imported or locally produced. 
2. Members may exclude from patentability inventions, the prevention within their territory of 
the commercial exploitation of which is necessary to protect ordre public or morality, including 
to protect human, animal or plant life or health or to avoid serious prejudice to the environment, 
provided that such exclusion is not made merely because the exploitation is prohibited by their 
law. 
3. Members may also exclude from patentability: 
    (a)    diagnostic, therapeutic and surgical methods for the treatment of humans or animals; 
    (b)    plants and animals other than micro-organisms, and essentially biological processes for 
the production of plants or animals other than non-biological and microbiological processes. 
However, Members shall provide for the protection of plant varieties either by patents or by an 
effective sui generis system or by any combination thereof. The provisions of this subparagraph 
shall be reviewed four years after the date of entry into force of the WTO Agreement. 
Article 28 [Rights Conferred] 
1.    A patent shall confer on its owner the following exclusive rights: 
    (a) where the subject matter of a patent is a product, to prevent third parties not having the 
owner's consent from the acts of: making, using, offering for sale, selling, or importing (2) for 
these purposes that product; 
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    (b) where the subject matter of a patent is a process, to prevent third parties not having the 
owner's consent from the act of using the process, and from the acts of: using, offering for sale, 
selling, or importing for these purposes at least the product obtained directly by that process. 
2. Patent owners shall also have the right to assign, or transfer by succession, the patent and to 
conclude licensing contracts. 
  Article 29 [Conditions on Patent Applicants] 
1.    Members shall require that an applicant for a patent shall disclose the invention in a manner 
sufficiently clear and complete for the invention to be carried out by a person skilled in the art 
and may require the applicant to indicate the best mode for carrying out the invention known to 
the inventor at the filing date or, where priority is claimed, at the priority date of the application. 
2. Members may require an applicant for a patent to provide information concerning the 
applicant's corresponding foreign applications and grants. 
  Article 30 [Exceptions to Rights Conferred] 
    Members may provide limited exceptions to the exclusive rights conferred by a patent, 
provided that such exceptions do not unreasonably conflict with a normal exploitation of the 
patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking 
account of the legitimate interests of third parties. 
  Article 31 [Other Use Without Authorization of the Right Holder] 
    Where the law of a Member allows for other use (3) of the subject matter of a patent without 
the authorization of the right holder, including use by the government or third parties authorized 
by the government, the following provisions shall be respected: 
    (a) authorization of such use shall be considered on its individual merits; 
    (b) such use may only be permitted if, prior to such use, the proposed user has made efforts to 
obtain authorization from the right holder on reasonable commercial terms and conditions and 
that such efforts have not been successful within a reasonable period of time. This requirement 
may be waived by a Member in the case of a national emergency or other circumstances of 
extreme urgency or in cases of public non-commercial use. In situations of national emergency 
or other circumstances of extreme urgency, the right holder shall, nevertheless, be notified as 
soon as reasonably practicable. In the case of public non-commercial use, where the government 
or contractor, without making a patent search, knows or has demonstrable grounds to know that a 
valid patent is or will be used by or for the government, the right holder shall be informed 
promptly; 
    (c) the scope and duration of such use shall be limited to the purpose for which it was 
authorized, and in the case of semi-conductor technology shall only be for public non-
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commercial use or to remedy a practice determined after judicial or administrative process to be 
anti-competitive; 
    (d) such use shall be non-exclusive; 
    (e) such use shall be non-assignable, except with that part of the enterprise or goodwill which 
enjoys such use; 
    (f) any such use shall be authorized predominantly for the supply of the domestic market of 
the Member authorizing such use; 
    (g) authorization for such use shall be liable, subject to adequate protection of the legitimate 
interests of the persons so authorized, to be terminated if and when the circumstances which led 
to it cease to exist and are unlikely to recur. The competent authority shall have the authority to 
review, upon motivated request, the continued existence of these circumstances; 
    (h) the right holder shall be paid adequate remuneration in the circumstances of each case, 
taking into account the economic value of the authorization; 
    (i) the legal validity of any decision relating to the authorization of such use shall be subject to 
judicial review or other independent review by a distinct higher authority in that Member; 
    (j) any decision relating to the remuneration provided in respect of such use shall be subject to 
judicial review or other independent review by a distinct higher authority in that Member; 
    (k) Members are not obliged to apply the conditions set forth in subparagraphs (b) and (f) 
where such use is permitted to remedy a practice determined after judicial or administrative 
process to be anti-competitive. The need to correct anti-competitive practices may be taken into 
account in determining the amount of remuneration in such cases. Competent authorities shall 
have the authority to refuse termination of authorization if and when the conditions which led to 
such authorization are likely to recur; 
    (l) where such use is authorized to permit the exploitation of a patent (“the second patent”) 
which cannot be exploited without infringing another patent (“the first patent”), the following 
additional conditions shall apply: 
        (i) the invention claimed in the second patent shall involve an important technical advance 
of considerable economic significance in relation to the invention claimed in the first patent; 
        (ii) the owner of the first patent shall be entitled to a cross-licence on reasonable terms to 
use the invention claimed in the second patent; and 
        (iii) the use authorized in respect of the first patent shall be non-assignable except with the 
assignment of the second patent. 
 66 
  Article 32 [Revocation/Forfeiture] 
    An opportunity for judicial review of any decision to revoke or forfeit a patent shall be 
available. 
  Article 33 [Term of Protection] 
    The term of protection available shall not end before the expiration of a period of twenty years 
counted from the filing date (4) 
  Article 34 [Process Patents: Burden of Proof] 
1. For the purposes of civil proceedings in respect of the infringement of the rights of the owner 
referred to in paragraph 1(b) of Article 28, if the subject matter of a patent is a process for 
obtaining a product, the judicial authorities shall have the authority to order the defendant to 
prove that the process to obtain an identical product is different from the patented process. 
Therefore, Members shall provide, in at least one of the following circumstances, that any 
identical product when produced without the consent of the patent owner shall, in the absence of 
proof to the contrary, be deemed to have been obtained by the patented process: 
    (a) if the product obtained by the patented process is new; 
    (b) if there is a substantial likelihood that the identical product was made by the process and 
the owner of the patent has been unable through reasonable efforts to determine the process 
actually used. 
2. Any Member shall be free to provide that the burden of proof indicated in paragraph 1 shall be 
on the alleged infringer only if the condition referred to in subparagraph (a) is fulfilled or only if 
the condition referred to in subparagraph (b) is fulfilled. 
3. In the adduction of proof to the contrary, the legitimate interests of defendants in protecting 
their manufacturing and business secrets shall be taken into account. 
 
Notes: 
 
(1) For the purposes of this Article, the terms “inventive step” and “capable of industrial 
application” may be deemed by a Member to be synonymous with the terms “non-obvious” and 
“useful” respectively. 
(2) This right, like all other rights conferred under this Agreement in respect of the use, sale, 
importation or other distribution of goods, is subject to the provisions of Article 6.   
(3) “Other use” refers to use other than that allowed under Article 30  
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(4) It is understood that those Members which do not have a system of original grant may 
provide that the term of protection shall be computed from the filing date in the system of 
original grant.  
http://www.wto.org/english/tratop_e/trips_e/t_agm3c_e.htm#5 
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A.3. Doha WTO Ministerial 2001: Declaration on the TRIPS Agreement 
and Public Health, Nov 20th, 2001 
 
http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm 
 
1. We recognize the gravity of the public health problems afflicting many developing and least-
developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other 
epidemics. 
2. We stress the need for the WTO Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS Agreement) to be part of the wider national and international action to address 
these problems. 
3. We recognize that intellectual property protection is important for the development of new 
medicines. We also recognize the concerns about its effects on prices. 
4. We agree that the TRIPS Agreement does not and should not prevent members from taking 
measures to protect public health. Accordingly, while reiterating our commitment to the TRIPS 
Agreement, we affirm that the Agreement can and should be interpreted and implemented in a 
manner supportive of WTO members' right to protect public health and, in particular, to promote 
access to medicines for all. 
In this connection, we reaffirm the right of WTO members to use, to the full, the provisions in 
the TRIPS Agreement, which provide flexibility for this purpose. 
5. Accordingly and in the light of paragraph 4 above, while maintaining our commitments in the 
TRIPS Agreement, we recognize that these flexibilities include: 
. In applying the customary rules of interpretation of public international law, each provision of 
the TRIPS Agreement shall be read in the light of the object and purpose of the 
Agreement as expressed, in particular, in its objectives and principles. 
-1. Each member has the right to grant compulsory licences and the freedom to determine the 
grounds upon which such licences are granted. 
-1. Each member has the right to determine what constitutes a national emergency or other 
circumstances of extreme urgency, it being understood that public health crises, including 
those relating to HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a 
national emergency or other circumstances of extreme urgency. 
-1. The effect of the provisions in the TRIPS Agreement that are relevant to the exhaustion of 
intellectual property rights is to leave each member free to establish its own regime for 
such exhaustion without challenge, subject to the MFN and national treatment provisions 
of Articles 3 and 4. 
6. We recognize that WTO members with insufficient or no manufacturing capacities in the 
pharmaceutical sector could face difficulties in making effective use of compulsory licensing 
under the TRIPS Agreement. We instruct the Council for TRIPS to find an expeditious solution 
to this problem and to report to the General Council before the end of 2002. 
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7. We reaffirm the commitment of developed-country members to provide incentives to their 
enterprises and institutions to promote and encourage technology transfer to least-developed 
country members pursuant to Article 66.2. We also agree that the least-developed country 
members will not be obliged, with respect to pharmaceutical products, to implement or apply 
Sections 5 and 7 of Part II of the TRIPS Agreement or to enforce rights provided for under these 
Sections until 1 January 2016, without prejudice to the right of least-developed country members 
to seek other extensions of the transition periods as provided for in Article 66.1 of the TRIPS 
Agreement. We instruct the Council for TRIPS to take the necessary action to give effect to this 
pursuant to Article 66.1 of the TRIPS Agreement.  
 
http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm 
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Appendix B:  Data 
B.1. Population in Thousands 
http://esa.un.org 
 
 
World Medium  High  Low constant 
1 5 279 519 5 279 519 5 279 519 5 279 519 
2 5 692 353 5 692 353 5 692 353 5 692 353 
3 6 085 572 6 085 572 6 085 572 6 085 572 
4 6 464 750 6 464 750 6 464 750 6 464 750 
5 6 842 923 6 903 276 6 781 431 6 881 529 
6 7 219 431 7 382 434 7 054 584 7 337 041 
7 7 577 889 7 873 172 7 280 148 7 819 287 
8 7 905 239 8 336 867 7 471 426 8 321 838 
9 8 199 104 8 784 155 7 618 083 8 855 299 
0 8 463 265 9 237 907 7 712 423 9 439 779 
11 8 701 319 9 709 446 7 753 745 10 092 723 
12 8 907 417 10 184 739 7 741 810 10 827 058 
13 9 075 903 10 646 311 7 679 714 11 657 999 
     
    
     
     
More developed    
1990 1 148 572 1 148 572 1 148 572 1 148 572 
1995 1 173 983 1 173 983 1 173 983 1 173 983 
2000 1 193 354 1 193 354 1 193 354 1 193 354 
2005 1 211 265 1 211 265 1 211 265 1 211 265 
2010 1 225 678 1 236 012 1 215 277 1 224 603 
2015 1 236 561 1 262 834 1 210 085 1 233 679 
2020 1 244 413 1 289 550 1 198 800 1 238 658 
2025 1 248 954 1 312 272 1 185 003 1 239 736 
2030 1 250 658 1 333 175 1 168 279 1 237 269 
2035 1 249 903 1 355 347 1 147 542 1 231 312 
2040 1 247 071 1 381 006 1 121 890 1 221 875 
2045 1 242 398 1 409 776 1 091 378 1 209 441 
2050 1 236 200 1 439 850 1 057 485 1 195 081 
     
     
     
     
     
     
Less developed    
1990 4 130 947 4 130 947 4 130 947 4 130 947 
1995 4 518 369 4 518 369 4 518 369 4 518 369 
 71 
2000 4 892 218 4 892 218 4 892 218 4 892 218 
2005 5 253 484 5 253 484 5 253 484 5 253 484 
2010 5 617 246 5 667 265 5 566 154 5 656 926 
2015 5 982 871 6 119 600 5 844 499 6 103 363 
2020 6 333 475 6 583 622 6 081 348 6 580 629 
2025 6 656 285 7 024 595 6 286 423 7 082 103 
2030 6 948 446 7 450 980 6 449 804 7 618 030 
2035 7 213 362 7 882 561 6 564 881 8 208 467 
2040 7 454 248 8 328 440 6 631 856 8 870 848 
2045 7 665 019 8 774 963 6 650 432 9 617 618 
2050 7 839 702 9 206 461 6 622 229 10 462 918 
 
Year 
World 
population 
Most 
Developed 
Less 
Developed 
Least 
Developed  
1990 5279519 1148572 4130947 521816  
1995 5692353 1173983 4518369 596962  
2000 6085572 1193345 4892218 673524  
2005 6464750 1211265 5253484 759389  
2010 6842923 1225678 5617246 852025  
2015 7219431 1236561 5982871 951610  
2020 7577889 1244413 6333475 1057086  
2025 7905239 1248954 6656285 1167461  
2030 8199104 1250658 6948446 1281335  
2035 8463265 1249903 7213362 1397057  
2040 8701319 1247071 7454248 1512643  
2045 8907417 1242398 7665019 1626025  
2050 9075903 1236200 7839702 1735368  
      
      
      
 (in millions)     
Year 
World 
Population 
Most 
Developed  
Less 
Developed 
Least 
Developed 
1990 5279.519 1148.572 4130.947 521.816  
1995 5692.353 1173.983 4518.369 596.962  
2000 6085.572 1193.345 4892.218 673.524  
2005 6464.75 1211.265 5253.484 759.389  
2010 6842.923 1225.678 5617.246 852.025  
2015 7219.431 1236.561 5982.871 951.61  
2020 7577.889 1244.413 6333.475 1057.086  
2025 7905.239 1248.954 6656.285 1167.461  
2030 8199.104 1250.658 6948.446 1281.335  
2035 8463.265 1249.903 7213.362 1397.057  
2040 8701.319 1247.071 7454.248 1512.643  
2045 8907.417 1242.398 7665.019 1626.025  
2050 9075.903 1236.2 7839.702 1735.368  
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B.2 World’s Largest Pharmaceutical Markets (1999-2005): Sales in 
Billions of 79.1% of World’s Industry 
 
 
 1999 2005 
USA (51.7%) 130.1 181.8 
Japan (17.3%) 53.5 61 
Germany 
(7.7%) 18.5 27 
France (6.3%) 17.8 22.5 
Italy (4.2%) 11.3 14.6 
UK (4.3%) 11 15.2 
Spain (3.1%) 6.6 10.9 
Brazil (1.9%) 6.2 6.8 
Canada 
(3.4%) 6.5 11.9 
  351.7 
   
Canada 6.5 11.9 
Brazil 6.2 6.8 
Spain 6.6 10.9 
UK 11 15.2 
Italy 11.3 14.6 
France 17.8 22.5 
Germany 18.5 27 
Japan 53.5 61 
USA 130.1 181.8 
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B.3. Drug Price Comparison of Diclofanic Sodium (Voveran), 
Piroxican (Dolonex) and Ranitidine (Zantac) in India, Pakistan, 
Indonesia, UK, and USA (in USD) 
 
 
 India Pakistan Indonesia UK USA 
Diclofanic Sodium 
(Voveran)           
Ciba-Geigy 6.49 55.62 177.18 120.12 402.8 
Piroxicam (Dolonex)       
Pfizer  24.64 72.5 218.45 1064.8 1064.8 
Ranitidine   (Zantac)           
Glaxo 17.39 241.44 658.36 603.36 1200.8 
 
 
B.K. Keayla. TRIPS Agreement on Patent Laws: Impact on Pharmaceuticals and Health for All 
(1997) 
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B.4. Growth of Pharmaceutical Sales by Region in Billions (2000-2003) 
 
 
World 
Market 
North 
America Europe  Japan 
Latin 
america 
Asia, Africa 
& Australia 
2000 152.8 75.3 51.5 18.9 18.7 
2001 181.8 88 47.6 27.9 18.9 
2002 203.6 101.9 46.9 31.6 16.5 
2003 229.5 129.7 52.4 37.3 17.4 
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